Early phase trials in soft-tissue sarcomas: clinical benefit of inclusion in early lines of treatment, molecular screening, and histology-driven trials

BACKGROUND: The prognosis of patients with advanced soft-tissue sarcomas (STS) remains dismal, and systemic therapeutic options are limited. Early phase trials are becoming increasingly safe and effective. This study aimed to identify the prognostic factors for progression-free survival (PFS). PATIE...

Descripción completa

Detalles Bibliográficos
Autores principales: Nassif, E.F., Blay, J.-Y., Massard, C., Dufresne, A., Brahmi, M., Cassier, P., Ray-Coquard, I., Pautier, P., Leary, A., Sunyach, M.-P., Bahleda, R., Levy, A., Le Pechoux, C., Honoré, C., Mir, O., Le Cesne, A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9058915/
https://www.ncbi.nlm.nih.gov/pubmed/35255445
http://dx.doi.org/10.1016/j.esmoop.2022.100425

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9058915/
https://www.ncbi.nlm.nih.gov/pubmed/35255445
http://dx.doi.org/10.1016/j.esmoop.2022.100425

Ejemplares similares